In addition to blogging and featuring their own Web sites, some drug companies are cautiously entering the Twitter community as they seek additional outlets for reaching their audience.
You are here
P&T® Journal contents for August 2009
Warfarin is commonly used to prevent and treat thromboembolic disease, but it is difficult to administer at the correct dose, primarily because of variations in patient responses. With new advances in medicine, it may be possible to tailor pharmacotherapy based on a patient’s genetic profile.
Regulation, Distribution, Evaluation, and Related Controversies
Although one of the FDA’s main goals is to protect consumers from unsafe products, the off-label use of prescription drugs is quite common. The history and debate regarding the distribution of off-label drug information and the FDA’s inability to limit non-approved uses of pharmaceuticals are reviewed.
This conference covered requirements for FDA approval of medical devices, including classifications, premarket submissions, and 510(k) reviews. Investigational devices and humanitarian use devices are also presented.
Some of the topics covered at the ADA sessions included therapies for achieving glycemic control in patients with type-2 diabetes. The EULAR meeting featured discussions of agents such as abatacept (Orencia) and tumor necrosis factor inhibitors for rheumatoid arthritis.